Skip to main content

Advertisement

Log in

Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

There has been no study on the efficacy of lafutidine for patients with reflux esophagitis in Korea.

Aim

To evaluate the efficacy of a new-generation histamine-2 receptor antagonist, lafutidine, in comparison with famotidine in patients with reflux esophagitis.

Methods

This was a randomized, double-blind, non-inferiority trial enrolling patients with erosive esophagitis. The efficacy and safety of 20 mg lafutidine (treatment group) were compared with those of 40 mg famotidine (control group) and 20 mg omeprazole (reference group). The primary endpoint was the complete healing rates of reflux esophagitis on endoscopy after 8 weeks of treatment. The non-inferiority margin was assumed to be −15 %.

Results

The healing rates of reflux esophagitis on endoscopy after 8 weeks of treatment were 70.14 % (101/144) in the lafutidine, 63.45 % (92/145) in the famotidine, and 85.71 % (126/147) in the omeprazole group. The difference in healing rates between the lafutidine and famotidine groups was 6.69 % (95 % confidence interval = [−4.14 to 17.52]). In addition, lafutidine was superior to famotidine in clinical improvement (53.73 % vs. 39.55 %, P = 0.0200).

Conclusions

Lafutidine was non-inferior to famotidine in healing of reflux esophagitis. Lafutidine, however, was superior to famotidine in terms of symptom relief of reflux esophagitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol. 2005;100:747–753.

    Article  PubMed  Google Scholar 

  2. Bai Y, Du Y, Zou D, et al. Gastroesophageal reflux disease questionnaire (GerdQ) in real-world practice: a national multicenter survey on 8065 patients. J Gastroenterol Hepatol. 2013;28:626–631.

    Article  PubMed  Google Scholar 

  3. Cho YK, Kim GH, Kim JH, et al. Diagnosis of gastroesophageal reflux disease: a systematic review. Korean J Gastroenterol. 2010;55:279–295.

    Article  PubMed  Google Scholar 

  4. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006;4:398–407.

    Article  PubMed  Google Scholar 

  5. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;18:CD003244.

  6. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–2100.

    Article  PubMed  Google Scholar 

  7. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170:765–771.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–2128.

    Article  CAS  PubMed  Google Scholar 

  9. Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36:405–413.

    Article  CAS  PubMed  Google Scholar 

  10. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–790.

    Article  PubMed  Google Scholar 

  11. Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545–553.

    Article  CAS  PubMed  Google Scholar 

  12. Inamori M, Togawa J, Iwasaki T, et al. Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J Gastroenterol. 2005;40:453–458.

    Article  CAS  PubMed  Google Scholar 

  13. Nakano M, Ajioka H, Abe M, et al. Possible involvement of host defense mechanism in the suppression of rat acute reflux esophagitis by the particular histamine H2 receptor antagonist lafutidine. Pharmacology. 2012;90:205–211.

    Article  CAS  PubMed  Google Scholar 

  14. Saegusa Y, Ichikawa T, Iwai T, et al. Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 2008;43:531–537.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Edelsbrunner ME, Nakano M, Holzer P. Afferent signalling from the acid-challenged rat stomach is inhibited and gastric acid elimination is enhanced by lafutidine. BMC Gastroenterol. 2009;9:40.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Nakano M, Kitano S, Nanri M, et al. Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism. Eur J Pharmacol. 2011;658:236–241.

    Article  CAS  PubMed  Google Scholar 

  17. Higuchi K, Watanabe T, Tominaga K, et al. Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial. Inflammopharmacology. 2006;14:226–230.

    Article  CAS  PubMed  Google Scholar 

  18. Ohara S, Haruma K, Kinoshita Y, et al. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol. 2010;45:1219–1227.

    Article  PubMed  Google Scholar 

  19. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.

    Article  CAS  PubMed  Google Scholar 

  20. Boeckxstaens GE, Rohof WO. Pathophysiology of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2014;43:15–25.

    Article  PubMed  Google Scholar 

  21. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200.

    Article  PubMed  Google Scholar 

  22. Holzer P. Neural emergency system in the stomach. Gastroenterology. 1998;114:823–839.

    Article  CAS  PubMed  Google Scholar 

  23. Akiba Y, Kaunitz JD. Lafutidine, a protective H(2) receptor antagonist, enhances mucosal defense in rat esophagus. Dig Dis Sci. 2010;55:3063–3069.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease–current concepts and dilemmas. Am J Gastroenterol. 2001;96:303–314.

    CAS  PubMed  Google Scholar 

  25. Habu Y, Maeda K, Kusuda T, et al. “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol. 2005;40:1029–1035.

    Article  CAS  PubMed  Google Scholar 

  26. Reynolds JC. Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol Suppl. 1995;213:17–24.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by Boryung Pharmaceutical Co., Ltd.

Conflict of interest

All authors reported no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Yong Chan Lee or Sang Woo Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, E.H., Lee, Y.C., Chang, Y.W. et al. Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Dig Dis Sci 60, 1724–1732 (2015). https://doi.org/10.1007/s10620-014-3489-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3489-4

Keywords

Navigation